UOC di Chirurgia 2, A.O. San Paolo, Dipartimento di Medicina, Chirurgia ed Odontoiatria, Università degli Studi di Milano, via A. di Rudini 8, 20142, Milan, Italy.
Surg Endosc. 2012 Apr;26(4):1108-15. doi: 10.1007/s00464-011-2007-4. Epub 2011 Nov 2.
Aggressive treatment of intrahepatic recurrence of hepatocellular carcinoma (HCC) increases patients' survival. This study aimed to evaluate laparoscopic thermal ablation (TA) in the treatment of intrahepatic HCC recurrences.
A retrospective analysis was performed on 88 patients (REC group) who underwent laparoscopic TA after prior TA (66 patients.) or partial hepatic resection (HR) (22 patients) as initial local treatment. Another 170 patients with primary HCC tumors (PRIM group) were regarded as the control group.
The postoperative morbidity rates were similar for the patients with prior TA (18%) and those with prior HR (21%) (nonsignificant difference [NS]). The overall survival rates were not significantly different between the two groups (3-year survival rates of 59 and 78%, respectively; P = 0.1662). Moreover, the disease-free survival (DFS) rates did not differ significantly between the patients with prior TA and those with prior HR (3-year DFS of 21 and 8%, respectively; P = 0.1911). The incidences of morbidity in the whole REC (21%) and PRIM (20%) groups were similar (P = NS), and no mortality occurred in either group (0%). The cumulative 3-year survival rate was 63% in the REC group and 59% in the PRIM group (P = 0.5739), whereas the 3-year DFS rate was 17% in the REC group and 22% in the PRIM group (P = 0.5266).
Laparoscopic TA can be performed safely and may be effective for intrahepatic HCC recurrence after prior TA or HR. It leads to survival and DFS rates similar to those obtained using laparoscopic TA for primary HCC without increasing morbidity. Laparoscopic TA could be proposed as first-line treatment of intrahepatic HCC recurrence for selected patients.
积极治疗肝细胞癌(HCC)肝内复发可提高患者的生存率。本研究旨在评估腹腔镜热消融(TA)治疗肝内 HCC 复发的效果。
对 88 例(REC 组)既往接受过 TA(66 例)或部分肝切除术(HR)(22 例)作为初始局部治疗后接受腹腔镜 TA 的患者进行回顾性分析。另外 170 例原发性 HCC 肿瘤患者(PRIM 组)作为对照组。
既往接受 TA(18%)和 HR(21%)的患者术后发病率相似(无显著性差异[NS])。两组的总生存率无显著差异(3 年生存率分别为 59%和 78%;P=0.1662)。此外,既往接受 TA 和 HR 的患者之间无显著差异(3 年 DFS 分别为 21%和 8%;P=0.1911)。整个 REC(21%)和 PRIM(20%)组的发病率相似(P=NS),两组均无死亡(0%)。REC 组的累积 3 年生存率为 63%,PRIM 组为 59%(P=0.5739),而 REC 组的 3 年 DFS 率为 17%,PRIM 组为 22%(P=0.5266)。
腹腔镜 TA 治疗肝内 HCC 复发是安全有效的,可在既往接受过 TA 或 HR 治疗后使用。它的生存率和 DFS 率与使用腹腔镜 TA 治疗原发性 HCC 相似,而不会增加发病率。腹腔镜 TA 可作为选定患者肝内 HCC 复发的一线治疗方法。